M&A by necessity: Takeda and Shire
The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined…
Takeda/Shire Deal to Spark Pharma M&A Boom?
With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald…
Kobe: A Center of Excellence for Biomedical Innovation
Kenichi Tamiya, director for Biomedical Policy at the Kobe City Government and managing director of the Kobe Foundation for Biomedical Research and Innovation (FBRI), discusses the central Japanese city of…
Promoting Japanese Bio-industry Innovation
Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within…